CRL: 10-K Risk Factor Changes

2026 vs 2025  ·  SEC EDGAR  ·  2026-07-05
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

9
New Risks
6
Removed
27
Modified
27
Unchanged
🟢 New in Current Filing Severity10/10Det 10

Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition can have an adverse effect on our business and financial statements.

Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition, including laws and policies in areas such as trade, manufacturing, government purchasing, healthcare, intellectual property, regulatory…

Read full text

Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition, including laws and policies in areas such as trade, manufacturing, government purchasing, healthcare, intellectual property, regulatory enforcement and investment/development, can adversely affect our business and financial statements. The U.S. has experienced a rapid increase in new government regulations, including tariffs and proposed tariffs on imports from a wide range of markets and geographies, including some in which we operate. These tariffs/proposed tariffs have prompted retaliatory tariffs by a number of countries and a cycle of retaliatory tariffs by both the U.S. and other countries. We continue to monitor the global tariff environment and potential trade conflicts, sanctions and impediments that could impact our business. As of the date of this report a number of tariffs remain in effect, including significant tariffs between the U.S. and countries from which we obtain significant supply, such as Vietnam, Mauritius, Cambodia, and China. Collectively, this may adversely impact our operating margin and results of operations, for example, our costs and expenses related to our business activities and those of our customers and suppliers; demand for our products and our competitive positioning; the availability to us of certain products in certain countries; and our supply chain operations. Though the risks identified above in certain cases have already adversely impacted part of our business, the full impact of these tariffs and other actions on the Company and on our business partners remains highly uncertain and subject to rapid change.

🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟢 New in Current Filing Our review of potential strategic alternatives may not result in an executed or consummated transaction or other strategic alternative, and the process of reviewing strategic alternatives or the outcome could adversely affect our business. 🔒
🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟢 New in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟢 New in Current Filing Several of our product and service offerings, including our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business. 🔒
🔴 No Match in Current Filing If we are not successful in selecting and integrating the businesses and technologies we acquire or partner with, or if we do not manage our current and future site closures and divestitures, our business may be adversely impacted. 🔒
🟡 Modified Demand volatility and risk of credit losses from clients may adversely affect our business. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified We are required to comply with stringent, complex and evolving laws, rules, regulations and standards in many jurisdictions, as well as contractual obligations, relating to data privacy and security. Any actual or perceived failure to comply with these requirements could have a material adverse effect on our business. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified Changes in government regulation or in practices relating to the pharmaceutical or biotechnology industries, including potential healthcare reform, could decrease the need for the services we provide. 🔒
🟡 Modified If we are not successful in selecting and integrating the businesses and technologies we acquire or partner with, or if we do not manage our current and future site closures and divestitures, our business may be adversely impacted. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified Failure to execute our business strategy could adversely impact our growth and profitability. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified Legal and Regulatory Risk Factors 🔒
🔴 No Match in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🔴 No Match in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🔴 No Match in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🔴 No Match in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🔴 No Match in Current Filing CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 🔒
🟡 Modified Our operations might be affected by the occurrence of a natural disaster or other catastrophic event. 🔒
🟡 Modified Business and Operational Risks 🔒
🟡 Modified We may not be able to successfully develop and market new services and products. 🔒
🟡 Modified Contaminations in our animal populations can damage our inventory, harm our reputation for contaminant-free production, result in decreased sales and cause us to incur additional costs. 🔒
🟡 Modified Our business is subject to risks relating to operating internationally, including changes in foreign currency exchange rates. 🔒
🟡 Modified We depend on key personnel and may not be able to retain these employees, which could harm our business. 🔒
🟡 Modified Impairment of long-lived tangible assets and intangible assets (such as goodwill and other intangible assets) may adversely impact future results of operations. 🔒
🟡 Modified New technologies may be developed, validated and increasingly used in biomedical research, which could reduce demand for some of our products and services. 🔒
🟡 Modified Our quarterly operating results may vary, which could negatively affect the market price of our common stock. 🔒
🟡 Modified If we are unable to attract, hire or retain key team members or a highly skilled global workforce with various backgrounds and experiences, it could have a negative impact on our business, financial condition or results of operations. 🔒
🟡 Modified We bear financial risk for contracts that may be terminated or reduced in scope, underpriced, subject to cost overruns or delays. 🔒
🟡 Modified The industries in which we operate are highly competitive. 🔒
🟡 Modified A reduction or delay in government funding of R&D may adversely affect our business. 🔒
41 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get full access — from $29/month Already a Pro subscriber? View full diff →